Candidate Treatment Gains Path for Newborn Brain Injury

Newborns with hypoxic-ischemic encephalopathy may eventually have a new option, though the drug has not yet been tested in this condition.

Updated on Nov. 2, 2026 in Autism

Photorealistic editorial photograph of a clear glass vial with pale amber liquid on a brushed steel laboratory bench, soft blue background, evoking early-stage pharmaceutical research.
Neuren Pharmaceuticals said the U.S. FDA granted orphan drug designation to its investigational drug NNZ-2591 for newborn hypoxic-ischemic encephalopathy, with an IND filing planned for the first half of 2027. AI Illustration. Upload story photo >

Australian drug developer Neuren Pharmaceuticals announced that the U.S. FDA granted Orphan Drug Designation to its investigational drug NNZ-2591 for neonatal hypoxic-ischemic encephalopathy (HIE), a brain injury in newborns. The company plans to submit an Investigational New Drug application in the first half of 2027.

Why it matters

HIE is a brain injury that occurs when a newborn's brain does not receive enough oxygen or blood flow before or shortly after birth, and this designation is a regulatory step that can support development of a treatment for that condition. The designation signals FDA recognition of the drug's potential for a rare condition, which can help speed the path toward clinical testing.

The designation is a regulatory status rather than a clinical finding, so no trial results for NNZ-2591 in HIE are reported. The announcement rests on the FDA's review of the drug's development plan for a condition affecting fewer than 200,000 U.S. patients.

The players

Neuren Pharmaceuticals

An Australian biopharmaceutical company listed on the ASX under the code NEU, developing treatments for neurodevelopmental conditions including Phelan-McDermid, Pitt Hopkins, and Angelman syndromes.

U.S. Food and Drug Administration

The U.S. agency that reviews and approves drugs and grants Orphan Drug Designation to therapies for rare diseases.

Jon Pilcher

Chief executive of Neuren Pharmaceuticals, who said the company looks forward to discussing the HIE development path with the FDA.

The details

Orphan Drug Designation is a program that encourages development of treatments for rare diseases by offering incentives such as market exclusivity and fee waivers. NNZ-2591 is already in clinical development for Phelan-McDermid syndrome, Pitt Hopkins syndrome, and Angelman syndrome, and it previously received orphan designation for those conditions. Before a clinical study in HIE can begin, Neuren is conducting a juvenile animal safety study that the FDA requires.

Timeline

  1. November 2, 2026: Neuren announced the FDA Orphan Drug Designation for NNZ-2591.

  2. First half of 2027: Neuren plans to submit its Investigational New Drug application for HIE.

Health Landscape

Neonatal HIE currently has limited pharmacological options, so new candidates entering development through the U.S. Orphan Drug program are a notable step for a condition defined by its acute onset at birth. The designation places NNZ-2591 among rare-disease therapies that receive FDA incentives during the years before clinical testing.

For families of newborns, HIE is a condition that is typically identified in the first hours after birth, so the designation mainly signals future options rather than current care. Anyone with questions about neonatal brain injury or how it is monitored should raise them with their child's neonatal care team.

The takeaway

A rare-disease designation is an early regulatory signal, not evidence that a treatment works, and no HIE trial has started yet. Parents and clinicians can keep an eye on the company's planned 2027 regulatory filing as the next checkpoint.

What happens next

Neuren plans to submit its Investigational New Drug application for NNZ-2591 in HIE in the first half of 2027, which will be the next regulatory milestone for the program.

Further reading

For more context on neurodevelopmental research, explore our Autism coverage.

Source note: This article includes information reported by Finance News Network.